Tag: Epicutaneous Immunotherapy (EPIT)
DBV Withdraws FDA Application for Viaskin Peanut with Plan to Resubmit
The company believes the additional information needed to support this filing is available without further clinical studies.
Non-Profit Institute to Review Benefits of Commercial, Private Practice Immunotherapies for...
An independent review of the value, costs and effectiveness of Viaskin Peanut, AR101, and private practice peanut OIT.
DBV Applies for FDA License to Sell Viaskin Peanut Patch Therapy
"This submission represents a significant step forward for those families living with peanut allergy."
Viaskin Peanut Completes Phase III Part A Study of Toddlers With...
Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
Study: Immunotherapy Trials for Food Allergy Hold Strong Appeal for Parents
Child’s food allergies have major impact on parents’ lives; majority of parents are willing to enroll their child in an immunotherapy clinical trial
Positive Safety Results Reported for Viaskin Peanut Phase III Trial
The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.
Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...
The study received higher-than-expected patient demand.
Adult Peanut Allergy: Therapy Cleared to Begin Phase IIa Trials
Antibody targets trigger also implicated in other food allergies, atopic diseases, and asthma.
Study: Peanut Immunotherapy Significantly Reduces Risks Due to Cross-Contact in Common...
The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.
Viaskin Patch Delivers Long-Lasting Peanut Desensitization After Phase IIb Trial
The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.
